These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 32305828)

  • 1. Drug Selection for Formulary Inclusion: An Exploratory Case Study of Oncology Medicines in Jordan.
    Alabbadi I; Almomani E; Alshazili M
    Value Health Reg Issues; 2020 May; 21():211-221. PubMed ID: 32305828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation and the Jordan Rational Drug List: an exploratory study of national-level priority setting.
    Lafi R; Robinson S; Williams I
    Value Health; 2012; 15(5):771-6. PubMed ID: 22867788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan.
    Hammad EA
    Value Health; 2016; 19(2):233-8. PubMed ID: 27021758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
    Weekes LM; Day RO
    Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
    Chabot I; Rocchi A
    Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary care physicians report high trust in and usefulness of the Stockholm drug and therapeutic committee's list of recommended essential medicines (the 'Wise List').
    Eriksen J; Ovesjö ML; Vallin M; Juhasz-Haverinen M; Andersén-Karlsson E; Ateva K; Gustafsson LL; Jirlow M; Bastholm-Rahmner P
    Eur J Clin Pharmacol; 2018 Jan; 74(1):131-138. PubMed ID: 29063149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
    Chalkidou K; Lord J; Obeidat NA; Alabbadi IA; Stanley AG; Bader R; Momani A; O'Mahony RM; Qatami L; Cutler D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):151-8. PubMed ID: 21473813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Priority-setting decisions for new cancer drugs: a qualitative case study.
    Martin DK; Pater JL; Singer PA
    Lancet; 2001 Nov; 358(9294):1676-81. PubMed ID: 11728542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of research abstracts in formulary decision making by the Joint Oncology Drug Review of Canada.
    Weizman AV; Griesman J; Bell CM
    Appl Health Econ Health Policy; 2010; 8(6):387-91. PubMed ID: 21043540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.
    Teerawattananon Y; Tantivess S; Yamabhai I; Tritasavit N; Walker DG; Cohen JT; Neumann PJ
    Health Res Policy Syst; 2016 Dec; 14(1):86. PubMed ID: 27912780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that influence prescribing decisions.
    Schumock GT; Walton SM; Park HY; Nutescu EA; Blackburn JC; Finley JM; Lewis RK
    Ann Pharmacother; 2004 Apr; 38(4):557-62. PubMed ID: 14966259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving use of cost-effectiveness analysis in formulary management within the Department of Veterans Affairs.
    Aspinall SL; Good CB; Glassman PA; Valentino MA
    Med Care; 2005 Jul; 43(7 Suppl):20-6. PubMed ID: 16056005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.
    Leonard MC; Thyagarajan R; Wilson AJ; Sekeres MA
    Am J Health Syst Pharm; 2018 Apr; 75(7):451-455. PubMed ID: 29572313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.